CD38 and COVID-19: Recent studies reported that, in many COVID-19 patients, CD8+ T cells presented the hyperactivation feature, including high levels of markers for cytotoxicity, increased numbers of CD38+HLA-DR+ activated population, and more Ki67+ proliferating cells [80–83].